Prognostic MicroRNAs After AMI

Abstract

The development of heart failure (HF) after acute myocardial infarction (AMI) is a prognostically important event, even in the context of early percutaneous coronary revascularization. The identification of patients at risk of developing HF remains an inexact science; even natriuretic peptides fail to provide accurate prognostication, in part, because of the fluctuations in plasma levels early after AMI.1 In the search for novel biomarkers, much interest has centered on circulating microRNAs (miRNAs), primarily focusing on cardiac-enriched miRNAs as diagnostic markers of AMI.2 Until recently, the prognostic value of circulating miRNAs in patients with AMI was poorly addressed. Matsumoto et al3 addressed the relevant question of whether circulating miRNAs may be used as predictors of prognosis after AMI. Plasma level of p53-responsive miR-192, miR-34a, and miR-194 were elevated in AMI patients who developed HF within the following year. In addition, miR-194 and miR-34a correlated with 1-year left ventricular …